The first thermic treatment predicts following chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer

  • Authors:
    • Hisanori Shoji
    • Masahiko Motegi
    • Kiyotaka Osawa
    • Takayuki Asao
    • Hiroyuki Kuwano
    • Takeo Takahashi
    • Kyoji Ogoshi
  • View Affiliations

  • Published online on: May 4, 2018     https://doi.org/10.3892/ol.2018.8630
  • Pages: 497-504
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The present study aimed to evaluate whether the neoadjuvant chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer can be predicted following the first thermic treatment. Eighty patients with primary rectal adenocarcinoma (≤12 cm from the anal verge) were included in this study. Fifty‑four received surgery and pathological response was evaluated. Intensity‑modulated radiotherapy was administered conventionally once daily 5 times/week. Neoadjuvant radiotherapy consisted of 50 Gy delivered to the planning target volume in 25 fractions. Concurrent neoadjuvant chemotherapy was delivered in 5‑day courses. Capecitabine was administered orally at 1,700 mg/m2/day for 5 days/week. Thermic treatment was performed using the Thermotron‑RF 8 and administered once/week for 5 weeks with 50 min irradiation. Patients with a gross tumor volume (GTV) ≤32 cm3 and a radiofrequency (RF) output difference (RO difference) ≥77 Watt/min exhibited pathological complete response (pCR) and CR rates of 50 and 75%, respectively. Those with a GTV ≥80 cm3 and a RO difference ≥77 Watt/min exhibited pCR and CR rates of 42.9 and 42.9%, respectively. The changes in the skin temperature during RF treatment in patients with pCR with a RO difference ≥77 Watt/min increased significantly compared with those of other outcomes, and progressive disease. These data suggest a strategy for predicting which patients will respond best following the first thermic treatment. The results identified that the group of patients with a GTV ≤32 cm3 and a RO difference ≥77 Watt/min (outputable/heatable patients) may respond best.
View Figures
View References

Related Articles

Journal Cover

July-2018
Volume 16 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Shoji H, Motegi M, Osawa K, Asao T, Kuwano H, Takahashi T and Ogoshi K: The first thermic treatment predicts following chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer. Oncol Lett 16: 497-504, 2018
APA
Shoji, H., Motegi, M., Osawa, K., Asao, T., Kuwano, H., Takahashi, T., & Ogoshi, K. (2018). The first thermic treatment predicts following chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer. Oncology Letters, 16, 497-504. https://doi.org/10.3892/ol.2018.8630
MLA
Shoji, H., Motegi, M., Osawa, K., Asao, T., Kuwano, H., Takahashi, T., Ogoshi, K."The first thermic treatment predicts following chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer". Oncology Letters 16.1 (2018): 497-504.
Chicago
Shoji, H., Motegi, M., Osawa, K., Asao, T., Kuwano, H., Takahashi, T., Ogoshi, K."The first thermic treatment predicts following chemoradiation response with concurrent thermal therapy for the treatment of rectal cancer". Oncology Letters 16, no. 1 (2018): 497-504. https://doi.org/10.3892/ol.2018.8630